Related Experiment Video
Updated: Jul 3, 2026
Antagonistic Effect of Jiawei Shengjiang San on a Rat Model of Diabetic Nephropathy: Related to EGFR/MAPK3/1 Signaling Pathway
Published on: May 10, 2024
[Protective effects of Shenkangwan against podocyte injury in rats with early diabetic nephropathy]
Hai-bo Long1, Hui Zhang, Juan Zhong
1Nephropathy Center of Integrated TCM and Western Medicine, Zhujiang Hospital, Southern Medical University, Guangzhou 510282, China. lymlhbcj@hotmail.com
Objective:
To investigate the morphological changes and expressions of desmin and podocin in podocytes of rats with diabetic nephropathy (DN) rats and renal protection mechanism of Shenkangwan.
Methods:
DN model was established in rats by a single injection of streptozotocin. The rats were then randomly divided into model group, Shenkangwan treatment group, irbesartan treatment group, and Shenkangwan plus irbesartan treatment group, with normal rats as the control group. All the rats received daily gavage for 8 weeks. The urinary protein quantity in 24 h were detected, and the morphological changes of the kidneys were observed with optic and transmission electron microscopes. The expressions of desmin and podocin in the podocytes were detected by immunohistochemistry.
Results:
Shenkangwan and irbesartan reduced the urinary protein quantity in 24 h and alleviated the renal damage in DN rats, and the expression of desmin was significantly attenuated while podocin expression increased in the podocytes.
Conclusions:
Shenkangwan can provide renal protection against DN in rats and alleviate the structural and functional damages of podocytes possibly by reducing desmin expression and increasing podocin expression in the podocytes.
Insights
Shenkangwan and irbesartan protect kidneys in diabetic nephropathy (DN) rats by reducing urinary protein and improving podocyte structure. Shenkangwan may achieve this by decreasing desmin and increasing podocin expression.
Area of Science:
- Nephrology
- Diabetology
- Pharmacology
Context:
- Diabetic nephropathy (DN) is a major complication of diabetes, leading to progressive kidney damage.
- Podocyte injury is a key factor in the development and progression of DN.
- Identifying effective therapeutic strategies for DN is crucial.
Purpose:
- To investigate the protective effects of Shenkangwan on podocyte injury in a rat model of DN.
- To explore the underlying mechanisms involving desmin and podocin expression.
- To compare the efficacy of Shenkangwan with irbesartan, a known renoprotective drug.
Summary:
- Diabetic nephropathy was induced in rats using streptozotocin.
- Rats were treated with Shenkangwan, irbesartan, or a combination for 8 weeks.
- Measurements included 24-hour urinary protein, kidney morphology, and podocyte desmin/podocin expression.
- Both Shenkangwan and irbesartan reduced proteinuria and renal damage.
- Shenkangwan treatment significantly decreased desmin expression and increased podocin expression in podocytes.
Impact:
- Shenkangwan demonstrates potential as a renoprotective agent for diabetic nephropathy.
- The findings suggest a mechanism involving the modulation of desmin and podocin in podocytes.
- This study provides evidence for the therapeutic value of Shenkangwan in managing DN complications.
Related Concept Videos
01:28Diabetic Nephropathy
01:27Diabetic Retinopathy